IGF2BP3 and breast cancer: Additionally, PD-L1-positive tissues expressed higher levels of METTL3 and PD-L1-negative tissues showed a concomitant decrease in IGF2BP3 expression, which suggested the existence of a METTL3-IGF2BP3-PD-L1 regulating axis in breast cancer (Fig. 6d).